Frank S. Rhame, M.D.
Dr. Rhame's experience in HIV medicine is extensive and stretches back to the early years of the epidemic in the United States. In 1987, he established the HIV Clinic at the University of Minnesota, which he directed through 1995. From 1987 to 1992 he co-directed the Minnesota AIDS Clinical Trials Unit. His work on HIV/AIDS has been published in dozens of journals and books, including AIDS, Clinical Infectious Diseases, JAIDS, the Journal of the American Medical Association and the New England Journal of Medicine. He has been a member of many National Institutes of Health review committees dealing with HIV-related research issues, and has been giving talks on HIV and the AIDS epidemic to clinicians since 1983. At Clinic 42, where he is research director, Dr. Rhame has conducted or overseen clinical trials on a considerable number of HIV antiretrovirals in development, as well as experimental HIV vaccines.
After earning his bachelor's degree in biology from the California Institute of Technology in 1964, Dr. Rhame attended Columbia University College of Physicians and Surgeons in New York, where he finished his medical education in 1968. He completed his internal medicine residency at University of Michigan Hospital and Stanford University Hospital, and stayed at Stanford for his infectious disease fellowship. He served on Stanford's clinical faculty until 1978, when the University of Minnesota offered him a tenure-track position within its School of Medicine.
In addition to his work on HIV in the United States, Dr. Rhame is also a well-traveled humanitarian. In the past seven years, he has participated in activities on infection control and AIDS care in Russia, Ukraine, Kenya and India, working for such organizations as the American International Health Alliance, Children's HeartLink, Medical Advocates for Social Justice, Nairobi Hospital and Universal Aid for Children, Inc.
Over the past two years, Dr. Rhame has advised, consulted for or received speaking honoraria from 3M, Abbott Laboratories, Aventis, Agouron/Pfizer, Bayer, Bristol-Myers Squibb Company, Boehringer Ingelheim, Gilead Sciences, Inc., GlaxoSmithKline, Merck & Co., Ortho Biotech Products, L.P., Roche, VGI and Wyeth. He has received investigator-initiated grants for clinical research from Merck.